Five Versus More Than Five Years of Tamoxifen for Lymph Node-Negative Breast Cancer: Updated Findings From the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial-Reference-Cited by-同舟云学术

Five Versus More Than Five Years of Tamoxifen for Lymph Node-Negative Breast Cancer: Updated Findings From the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial

Published:2001-05-02 Issue:9 Volume:93 Page:684-690
ISSN:0027-8874
Container-title:JNCI Journal of the National Cancer Institute
language:en
Short-container-title:JNCI Journal of the National Cancer Institute

Author:

Fisher B.,Dignam J.,Bryant J.,Wolmark N.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Reference19 articles.

1. A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive Tumors

2. Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive Tumors

3. Five Years of Tamoxifen--or More?

4. The optimal duration of adjuvant tamoxifen treatment for breast cancer remains uncertain: Randomize into aTTom

Cited by 538 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Defining the Need for Services for Patients at High Risk of Breast Cancer at a Safety-Net Hospital: An Approach to Narrowing the Disparities Gap;Annals of Surgical Oncology;2024-08-13

2. A case report of synchronous breast and lung cancer with three different pathologic diagnoses;AME Case Reports;2024-07

3. Systemic Therapy in Breast Cancer;American Society of Clinical Oncology Educational Book;2024-06-01

4. Association between pathological characteristics and recurrence score by OncotypeDX in resected T1-3 and N0-1 breast cancer: a real-life experience of a North Hungarian regional center;Pathology and Oncology Research;2024-04-16

5. Analyse des effets des inhibiteurs de l’aromatase en traitement prolongé chez les femmes ménopausées atteintes d’un cancer du sein non métastatique hormonodépendant ayant déjà reçu cinq ans d’hormonothérapie adjuvante : revue systématique et méta-analyse;Bulletin du Cancer;2024-04